drugset / Trial / NCT00301769
SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial is studying the side effects and best dose of SJG-136 in treating patients with relapsed or refractory acute leukemia, myelodysplastic syndromes, blastic phase chronic myelogenous leukemia, or chronic lymphocytic leukemia. Drugs used in chemotherapy, such as SJG-136, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Timeline
- Start
- 2005-12
- Primary completion
- 2009-02
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SJG-136 | Small molecule | — | Intravenous |
Indications
B-cell chronic lymphocytic leukemia
acute myeloid leukemia with 11q23 abnormalities
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
acute myeloid leukemia with t(8;21)(q22;q22) translocation
acute promyelocytic leukemia
adult acute lymphoblastic leukemia
blast phase chronic myelogenous leukemia, BCR-ABL1 positive
myelodysplastic syndrome